


Technical Report No. 54-3

Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations

Annex 2: Case Studies in the Manufacturing of Pharmaceutical Drug Products

PCMO
Paradigm Change in
Manufacturing OperationsSM



2013



PDA Team on Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations

Annex 2: Case Studies in the Manufacturing of Pharmaceutical Drug Products

Authors

William Harclerode, Forest Research Institute (*Chair*)

Karen Bossert, Ph.D., RPh, Lyophilization Technology

Marcia Borysthen, The Q: Pharmaceutical Quality Services

Olivier Chancel, Merial, a Sanofi company

Greta Davis, Lantheus Medical Imaging

David Doleski, U.S. FDA

Paul Fiorio, Novartis

Mary Beth Grace, Genentech

Ghada Haddad, Merck/Genentech

William Hunke, Ph.D., Sterile and Liquids Consulting LLC

Mihaela C. Simianu, Ph.D., Eli Lilly and Co

Anthony C. Warchut, PAREXEL Consulting

DISCLAIMER: This technical report was developed as part of PDA's Paradigm Change in Manufacturing Operations (PCMO) project. The content and views expressed in this Technical Report are the result of a consensus achieved by the Technical Report Team and are not necessarily views of the organizations they represent.

Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations

Annex 2: Case Studies in the Manufacturing of Pharmaceutical Drug Products

Technical Report No. 54-3

ISPN 08-0-939459-62-9

© 2012 Parenteral Drug Association, Inc.

All rights reserved.



Paradigm Change in Manufacturing Operations (PCMOSM)

PDA launched the project activities related to the PCMO program in December 2008 to help implement the scientific application of the ICH Q8, Q9 and Q10 series. The PDA Board of Directors approved this program in cooperation with the Regulatory Affairs and Quality Advisory Board, and the Biotechnology Advisory Board and Science Advisory Board of PDA.

Although there are a number of acceptable pathways to address this concept, the PCMO program follows and covers the drug product life cycle, employing the strategic theme of process robustness within the framework of the manufacturing operations. This project focuses on Pharmaceutical Quality Systems as an enabler of Quality Risk Management and Knowledge Management.


Using the Parenteral Drug Association's (PDA) membership expertise, the goal of the Paradigm Change in Manufacturing Operations Project is to drive the establishment of 'best practice' documents and /or training events in order to assist pharmaceutical manufacturers of Investigational Medicinal Products (IMPs) and commercial products in implementing the ICH guidelines on Pharmaceutical Development (ICH Q8, Q11), Quality Risk Management (ICH Q9) and Pharmaceutical Quality Systems (ICH Q10).

The PCMO program facilitates communication among the experts from industry, university and regulators as well as experts from the respective ICH Expert Working Groups and Implementation Working Group. PCMO task force members also contribute to PDA conferences and workshops on the subject.

PCMO follows the product life-cycle concept and has the following strategic intent:

- Enable an innovative environment for continual improvement of products and systems
- Integrate science and technology into manufacturing practice
- Enhance manufacturing process robustness, risk-based decision making and knowledge management
- Foster communication among industry and regulatory authorities

The Product Life Cycle



For more information, including the PCMO Dossier, and to get involved, go to www.pda.org/pcmo

Table of Contents

1.0 INTRODUCTION	1	4.3.2 Risk Identification and Analysis	22
1.1 Purpose and Scope.....	1	4.3.3 Determining Critical Control Points	24
2.0 GLOSSARY OF TERMS	2	4.3.4 Establishing Target Levels and Critical Limits.....	24
3.0 CASE STUDY 1: CONTROL OF VISIBLE PARTICULATES	3	4.3.5 Establishing a System to Monitor the CCPs	25
3.1 Executive Summary	3	4.4 Risk Control	26
3.2 Quality Risk Management Planning	3	4.4.1 Corrective Actions	26
3.2.1 Background	3	4.5 Risk Communication.....	27
3.2.2 Description and Scope.....	3	4.5.1 Risk Documentation	27
3.2.3 Team Selection	3	4.6 Risk Review.....	28
3.2.4 Process Flow	4	5.0 CASE STUDY 3: LYOPHILIZATION TECHNICAL TRANSFER/SCALE-UP RISK ANALYSIS	29
3.2.4.1 Processing of Containers and Closures	4	5.1 Executive Summary	29
3.2.4.2 Manufacturing Environment	4	5.2 Quality Risk Management Planning.....	29
3.2.4.3 Sterile Filtration and Filling	5	5.2.1 Background	29
3.2.4.4 Capping of Filled Vials	5	5.2.2 Description and Scope.....	29
3.2.4.5 Visual Inspection of Filled Vials	5	5.2.3 Team Selection	30
3.2.5 Risk Assessment Methodology	5	5.2.4 Process Flow	30
3.3 Risk Assessment.....	6	5.3 Risk Assessment	32
3.3.1 Risk Identification	6	5.4 Risk Control.....	35
3.3.2 Risk Analysis	6	5.5 Risk Communication.....	35
3.4 Risk Control.....	7	5.6 Risk Review.....	36
3.4.1 Risk Evaluation	7	6.0 CASE STUDY 4: MELAMINE CONTAMINATION (SUPPLY CHAIN)	37
3.4.1.1 High Risks and Recommended Actions.....	8	6.1 Executive Summary	37
3.4.1.2 Medium Risks and Recommended Actions	8	6.2 Quality Risk Management Planning.....	37
3.4.1.2 Low Risks and Recommended Actions	8	6.2.1 Background	37
3.5 Risk Communication.....	8	6.2.2 Description and Scope.....	37
3.6 Risk Review.....	8	6.2.3 Team Selection	37
4.0 CASE STUDY 2: COMBINATION PHARMACEUTICAL/ DEVICE PRODUCT (VIRAL CLEARANCE)	16	6.2.4 Process Flow	37
4.1 Executive Summary	16	6.3 Risk Assessment.....	39
4.2 Quality Risk Management Planning	16	6.4 Risk Control.....	41
4.2.1 Product Analysis	16	6.5 Risk Communication.....	41
4.2.2 Description and Scope.....	16	6.6 Risk Review.....	41
4.2.2.1 Product Description	16	7.0 CONCLUSION	42
4.2.2.2 Carrier Process Description	16	8.0 REFERENCES	43
4.2.3 Team Member Selection	17	9.0 ADDITIONAL READING	44
4.2.4 Process Flow	18		
4.3 Risk Assessment.....	19		
4.3.1 Initial Risk Reduction—Viral Validation.....	20		

FIGURES AND TABLES INDEX

Figure 3.2.4-1	Process Flow Diagram of Manufacture of an Injectable Drug Product 4	Table 4.3.1-2	Quality Risk Rating Criteria 21
Table 3.2.5-1	Type of Harm and Hazard by Process Step 5	Table 4.3.1-3	Risk Levels Based on RPNs 22
Table 3.3.2-1	Severity 6	Table 4.3.2-1	Hazard Prioritization 23
Table 3.3.2-2	Probability of Occurrence 7	Table 4.3.4-1	Excerpt from Table of CCPs for Parvovirus Control 25
Table 3.3.2-3	Detection 7	Table 4.3.5-1	Revised FMEA for Carrier Process: Risk of Using Animal-Derived Tissue ... 26
Table 3.3.2-4	RPNs Determined by Risk Prioritization Matrix 7	Table 4.6-1	HACCP Plan for Reduction of the Harm from Parvovirus 28
Table 3.4.1-1	Risk Acceptability Decision 8	Figure 5.2.2-1	Normal and Collapsed Cakes from Lyophilization 30
Table 3.6-1	Risk Assessment Table 9	Figure 5.2.4-1	Process Flow Diagram: The Lyophilization Process 31
Table 3.6-2	High Risks 13	Table 5.3-1	FMEA Table Items with Potential Failure Effect: Collapse, Meltback, or Partial Collapse 33
Table 3.6-3	Medium Risks for Stoppering 14	Table 5.3-2	Risk Prioritization Matrix 35
Table 3.6-4	Medium Risks for Vial Washing 14	Figure 6.2.4-1	Process Flow Diagram of Material Supply Chain 38
Table 3.6-5	Medium Risks for Depyrogenation 15	Figure 6.3-1	Preliminary Fault Tree Analysis (FTA) ... 39
Table 3.6-6	Medium Risks for Filling 15	Table 6.3-1	Severity of Patient Risk from 50% Melamine Contamination of Material .. 41
Table 3.6-7	Medium Risks for Capping 15	Table 6.3-2	Overall Patient Risk of Melamine Contamination (FMEA Analysis) 41
Figure 4.2.4-1	Process Flowchart for Carrier Intermediate Material 18		
Figure 4.2.4-2	Flow Chart for Viral Validation of Carrier Process 18		
Figure 4.2.4-3	Flow Chart for Chaotropic Process Step 19		
Table 4.3.1-1	FMEA for Carrier Process: Risk of Using Animal-Derived Tissue 21		

1.0 Introduction

Identification and management of risk in the pharmaceutical industry are vital to understanding pharmaceutical products and processes to minimize potential negative impacts on patients.

In the highly regulated pharmaceutical industry, it is important that significant risks be formally identified, reduced, controlled, and effectively communicated throughout the supply chain and the product lifecycle. Both industry leaders and regulatory authorities understand that some degree of risk is inherent in the manufacturing and use of drug products, but they share the common goal of protecting the patient. Formal risk-management tools can be used to effectively document and communicate this control.

ICH Quality Guideline Q9: Quality Risk Management presents general principles of risk management and examples of various risk management tools (1). However, Q9 does not provide details or how to use these tools in real-world pharmaceutical situations. This document is provided to bridge the gap using case studies from industry to illustrate how various risk management tools are applied.

Risk management is most effective when used prospectively during product development or conceptual design, when design and control systems are easily modified to reduce risk and improve product quality. Building quality into drug products up front is better than testing finished products for defects later. Nonetheless, risk management can also be effectively used for an actual defect in or incident involving a commercialized product to identify the root cause and prevent recurrences. Examples of prospective and reactive risk management approaches are included in these case studies.

These case studies were selected to represent some areas that are a current concern to our industry: particulates in liquid products, viral clearance in a combination product, lyophilization, and supply chain contamination. Use of several risk management tools is illustrated in these examples. The steps in the case studies are presented according to the QRM model from Q9 (risk assessment, risk control, risk communication, and risk review).

The benefits of QRM include providing proactive means to identify, control, and communicate quality issues; improve decision making; reduce regulatory compliance risk; and reduce patient risk. Every manufacturer's product and process is unique, and risk tolerance varies among manufacturers. Therefore, it is not possible to provide case studies and examples that fit every circumstance in pharmaceutical manufacturing. These case studies present the use of QRM in real-world situations but are only illustrative and represent just one way to manage risk.

1.1 Purpose and Scope

This document is a supplemental annex to PDA Technical Report No. 54, *Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations* (2). It provides specific case study examples of how to apply quality risk management (QRM) to the manufacturing of pharmaceutical drug products. This document is one in a series of similar documents that provide additional examples of how to apply risk management tools across the product supply chain, from the starting materials (active pharmaceutical ingredients [APIs] and excipients) through manufacturing to stoppering and capping.

NOTE: There is no one way to apply QRM. The technical report team chose these four case studies to illustrate the adaptability of QRM tools to help solve various problems, implement corrective actions, and keep processes in a state of control.